Study Looking at Treatments for Recurrent Glioblastoma

What we are studying

The purpose of this research study is to find out what effects, good and/or bad, the combination of dasatinib and bevacizumab has on recurrent glioblastoma.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Must have grade 3 or 4 glioma

What is involved

  • Routine tests and exams
  • Taking two tablets of either dasatinib or placebo orally twice a day both morning and evening on days 1 through 14

Compensation

None

Contact Information

Study Coordinator
Michele Harmon
Email
mharmon@wakehealth.edu
Phone
336-713-6925

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.